Erbitux cetuximab: Additional Phase III data

Additional data from the open-label, Chinese Phase III TAILOR trial in 397 patients with wild-type Ras mCRC showed that first-line treatment with Erbitux plus FOLFOX-4 chemotherapy met the secondary endpoints of improving median OS (20.7 vs. 17.8 months, p=0.02) and ORR (61.1% vs. 39.5%, p<0.001) vs. FOLFOX-4 alone. Merck previously reported data that Erbitux plus FOLFOX-4 met the primary endpoint of improving median PFS vs. FOLFOX-4 alone (9.2 vs. 7.4 months, p=0.004) (see BioCentury, May 2). Data were presented at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer in Barcelona. ...